These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 7825760

  • 21. Treatment of chronic myeloid leukemia with interferon alpha (Roferon): results of the Israeli Study Group on CML.
    Shtalrid M, Lugassy G, Rosensaft J, Berrebi A.
    Leuk Lymphoma; 1993; 11 Suppl 1():193-7. PubMed ID: 8251895
    [Abstract] [Full Text] [Related]

  • 22. [Treatment with interferon alfa-2a in the chronic phase of Philadelphia-positive chronic myeloid leukemia].
    Steegmann JL, Lavilla E, Somolinos N, Pérez-Sánchez M, Lamana M, Olmeda F, Cámara R, Arranz R, Ferro MT, Fernández-Rañada JM.
    Sangre (Barc); 1992 Oct; 37(5):375-81. PubMed ID: 1293778
    [Abstract] [Full Text] [Related]

  • 23. A cytogenetic and fluorescence in situ hybridization evaluation of interferon-alpha in the treatment of chronic myeloid leukemia.
    Itoh T, Tamura S, Takemoto Y, Kakishita E.
    Int J Mol Med; 1999 Dec; 4(6):659-63. PubMed ID: 10567680
    [Abstract] [Full Text] [Related]

  • 24. Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013.
    Silver RT, Peterson BL, Szatrowski TP, Powell BL, Stock W, Carroll AJ, Bloomfield CD, Schiffer CA, Larson RA.
    Leuk Lymphoma; 2003 Jan; 44(1):39-48. PubMed ID: 12691141
    [Abstract] [Full Text] [Related]

  • 25. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis.
    Kantarjian HM, O'Brien S, Cortes JE, Shan J, Giles FJ, Rios MB, Faderl SH, Wierda WG, Ferrajoli A, Verstovsek S, Keating MJ, Freireich EJ, Talpaz M.
    Cancer; 2003 Feb 15; 97(4):1033-41. PubMed ID: 12569603
    [Abstract] [Full Text] [Related]

  • 26. A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia.
    Anger B, Porzsolt F, Leichtle R, Heinze B, Bartram C, Heimpel H.
    Blut; 1989 Jun 15; 58(6):275-8. PubMed ID: 2736308
    [Abstract] [Full Text] [Related]

  • 27. GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia.
    Cortes J, Kantarjian H, O'Brien S, Kurzrock R, Keating M, Talpaz M.
    Leukemia; 1998 Jun 15; 12(6):860-4. PubMed ID: 9639411
    [Abstract] [Full Text] [Related]

  • 28. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
    Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Rios MB, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Verstovsek S, Wierda W, Keating M, Talpaz M.
    Cancer; 2003 Dec 15; 98(12):2636-42. PubMed ID: 14669283
    [Abstract] [Full Text] [Related]

  • 29. Response to recombinant interferon alpha in patients with chronic myelogenous leukemia in a single center: results and analysis of predictive factors.
    Montastruc M, Mahon FX, Fabères C, Marit G, Bilhou-Nabera C, Cony-Makhoul P, Puntous M, Pigneux A, Boiron JM, Bernard P.
    Leukemia; 1995 Dec 15; 9(12):1997-2002. PubMed ID: 8609708
    [Abstract] [Full Text] [Related]

  • 30. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group.
    Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau JL, Maloisel F, Bouabdallah R, Guyotat D, Cheron N, Nicolini F, Abgrall JF, Tanzer J.
    N Engl J Med; 1997 Jul 24; 337(4):223-9. PubMed ID: 9227927
    [Abstract] [Full Text] [Related]

  • 31. Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of Philadelphia chromosome-negative cells in chronic myelogenous leukemia.
    Kantarjian HM, Talpaz M, LeMaistre CF, Spinolo J, Spitzer G, Yau J, Dicke K, Jagannath S, Deisseroth AB.
    Cancer; 1991 Jun 15; 67(12):2959-65. PubMed ID: 1675151
    [Abstract] [Full Text] [Related]

  • 32. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
    Kantarjian H, O'Brien S, Cortes J, Shan J, Giles F, Garcia-Manero G, Verstovsek S, Faderl S, Rios MB, Talpaz M.
    Cancer; 2003 Oct 01; 98(7):1430-7. PubMed ID: 14508830
    [Abstract] [Full Text] [Related]

  • 33. Impact of interferon alpha-induced cytogenetic improvement on survival in chronic myelogenous leukaemia.
    Kloke O, Niederle N, Qiu JY, Wandl U, Moritz T, Nagel-Hiemke M, Hawig I, Opalka B, Seeber S, Becher R.
    Br J Haematol; 1993 Mar 01; 83(3):399-403. PubMed ID: 8485045
    [Abstract] [Full Text] [Related]

  • 34. Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Kantarjian HM, Talpaz M, Keating MJ, Estey EH, O'Brien S, Beran M, McCredie KB, Gutterman J, Freireich EJ.
    Cancer; 1991 Sep 15; 68(6):1201-7. PubMed ID: 1873771
    [Abstract] [Full Text] [Related]

  • 35. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Kantarjian H, Talpaz M, O'Brien S, Giles F, Rios MB, White K, Garcia-Manero G, Ferrajoli A, Verstovsek S, Wierda W, Kornblau S, Cortes J.
    Cancer; 2003 May 01; 97(9):2225-8. PubMed ID: 12712475
    [Abstract] [Full Text] [Related]

  • 36. [Therapy of chronic myeloid leukemia with interferon].
    Fülle HH, Dahmen E, Hellriegel KP.
    Onkologie; 1988 Aug 01; 11(4):177-83. PubMed ID: 3054669
    [Abstract] [Full Text] [Related]

  • 37. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia.
    Allan NC, Richards SM, Shepherd PC.
    Lancet; 1995 Jun 03; 345(8962):1392-7. PubMed ID: 7760609
    [Abstract] [Full Text] [Related]

  • 38. Combined therapy interferon and chemotherapy in chronic myelogenous leukemia.
    Guilhot F, Dreyfus B, Desmarest MC, Giraud C, Huret JL, Brizard A, Tanzer J.
    Nouv Rev Fr Hematol (1978); 1989 Jun 03; 31(2):171-3. PubMed ID: 2771633
    [Abstract] [Full Text] [Related]

  • 39. The German CML study, comparison of busulfan vs. hydroxyurea vs. interferon alpha and establishment of prognostic score 1.
    Hehlmann R, Heimpel H, Kolb HJ, Heinze B, Hochhaus A, Griesshammer M, Pralle H, Queisser WP, Essers U, Falge C.
    Leuk Lymphoma; 1993 Jun 03; 11 Suppl 1():159-68. PubMed ID: 8251890
    [Abstract] [Full Text] [Related]

  • 40. The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon alpha.
    Hasford J, Pfirrmann M, Shepherd P, Guilhot J, Hehlmann R, Mahon FX, Kluin-Nelemans HC, Ohnishi K, Steegmann JL, Thaler J.
    Haematologica; 2005 Mar 03; 90(3):335-40. PubMed ID: 15749665
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.